Masimo (NASDAQ:MASI) and Magna-Lab (OTCMKTS:MAGAA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Institutional & Insider Ownership
83.0% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Comparatively, 15.3% of Magna-Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Masimo and Magna-Lab, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Masimo currently has a consensus target price of $154.50, indicating a potential upside of 0.05%. Given Masimo’s higher probable upside, research analysts clearly believe Masimo is more favorable than Magna-Lab.
This table compares Masimo and Magna-Lab’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Masimo and Magna-Lab’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Masimo||$858.29 million||9.60||$193.54 million||$3.03||50.97|
Masimo has higher revenue and earnings than Magna-Lab.
Risk and Volatility
Masimo has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 8.72, indicating that its share price is 772% more volatile than the S&P 500.
Masimo beats Magna-Lab on 8 of the 10 factors compared between the two stocks.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software that monitors Masimo Root and Radical-7. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, long term care facilities, veterinarians and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Magna-Lab, Inc. is a shell company, which intends to identify and merge with an operating company. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Syosset, NY.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.